Published in Am J Med on April 01, 2013
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep (2013) 0.98
Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol (2013) 0.82
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? Oncologist (2015) 0.82
Myelodysplastic syndromes: what do hospitalists need to know? J Hosp Med (2013) 0.81
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling? Expert Rev Hematol (2014) 0.75
Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation? Expert Rev Hematol (2013) 0.75
Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? Am J Hematol (2015) 0.75
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med (2014) 0.75
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med (2016) 0.75
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Myelodysplastic syndromes: therapy and outlook. Am J Med (2012) 1.51
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer (2011) 1.10
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res (2013) 2.24
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood (2011) 2.14
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Acute myeloid leukemia. J Natl Compr Canc Netw (2012) 1.96
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res (2009) 1.92
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82
Cancer stem cells: are we missing the target? J Natl Cancer Inst (2004) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res (2010) 1.63
The paradox of response and survival in cancer therapeutics. Blood (2005) 1.63
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol (2012) 1.61
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol (2008) 1.59
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol (2011) 1.59
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma (2012) 1.57
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant (2009) 1.53
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol (2010) 1.50
Arsenic trioxide - An old drug rediscovered. Blood Rev (2010) 1.49
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.47
Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells (2011) 1.45
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res (2008) 1.43
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma (2004) 1.41
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol (2005) 1.41
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood (2005) 1.38
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood (2011) 1.36
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol (2010) 1.26
Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw (2013) 1.26
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs (2011) 1.25
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol (2014) 1.23
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res (2007) 1.23
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res (2005) 1.23
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol (2005) 1.22
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood (2012) 1.21
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood (2011) 1.20
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood (2007) 1.19
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood (2005) 1.18
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2010) 1.18
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant (2011) 1.17
Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma (2002) 1.15
Characterization of chronic myeloid leukemia stem cells. Am J Hematol (2011) 1.15
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer (2010) 1.14
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma (2010) 1.13
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw (2013) 1.12
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem (2003) 1.12
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res (2009) 1.09
Acute myeloid leukemia. J Natl Compr Canc Netw (2011) 1.09
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol (2009) 1.09
Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw (2013) 1.07
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program (2003) 1.07
A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica (2009) 1.04
Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.02
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol (2010) 1.02
Decitabine. Nat Rev Drug Discov (2006) 1.02
Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer (2006) 1.02
Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw (2014) 1.02
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res (2012) 1.01
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant (2006) 0.99
Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res (2014) 0.98
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther (2010) 0.98
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep (2013) 0.98
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem (2011) 0.97
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk (2013) 0.96
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood (2013) 0.96
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer (2011) 0.95
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res (2011) 0.95